Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Eli Lilly (LLY) recently collaborated with Superluminal Medicines to advance therapeutics targeting cardiometabolic diseases, ...

Eli Lilly has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs ...

Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Superluminal Medicines has confirmed that it signed a deal with US drugmaker Eli... Phil Bishop, the chief operating officer of gambling giant Flutter, has sold shares... Gold prices were subdued on ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets. The ...